Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Pecherstorfer

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Cancers|October 13, 2021
Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple MyelomaSamantha Pozzi, Alessia Bari, Martin Pecherstorfer, et al.
Oncology Letters|June 12, 2025
Real-world evidence of imatinib treatment in younger and older patients with chronic myeloid leukaemia: A retrospective single centre analysisRebecca Graf, Gudrun Kreye, Martin Pecherstorfer, et al.
Molecular and Clinical Oncology|December 6, 2024
Treatment of stage IV colorectal cancer: A retrospective cohort study assessing whether failure of first‑line treatment indicates failure of second‑line treatmentHanna Peyerl, Gudrun Kreye, Martin Pecherstorfer, et al.
Translational Oncology|February 23, 2021
Evaluation of personalized cancer therapies based on comprehensive genomic profiling in a middle-sized oncologic center in Austria, the University Clinic KremsJosef Singer, Elias Brauneck, Elisabeth Zwickl-Traxler, et al.
Oncotarget|July 26, 2018
Tolerability of obinutuzumab therapy in patients with rituximab-relapsed/refractory B-cell malignancies - a retrospective single center cohort studyTheo Pirich, Elisabeth Zwickl-Traxler, Martin Pecherstorfer, et al.
Oncotarget|March 2, 2018
Evaluation of vascular events in patients with myeloproliferative syndromes and mutations of either the januskinase-2 or calreticulin gene at the university hospital Krems from 2008 to 2015Sarah Hintermair, Elisabeth Zwickl-Traxler, Martin Pecherstorfer, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
Evaluation of Ki-67 as a Prognostic Marker in Diffuse Large B-Cell Lymphoma-A Single-Center Retrospective Cohort StudyFabian Huber, Elisabeth Zwickl-Traxler, Martin Pecherstorfer, et al.
Pharmaceutics|October 26, 2018
Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment StrategiesSonia Vallet, Julia-Marie Filzmoser, Martin Pecherstorfer, et al.
Clinical Drug Investigation|December 14, 2006
Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trialMartin Pecherstorfer, Saul Rivkin, Jean-Jacques Body, et al.
Leukemia & Lymphoma|January 19, 2018
A role for bone turnover markers β-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myelomaSonia Vallet, Nicholas R Hoyle, Robert A Kyle, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Cancers|October 13, 2021
Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple MyelomaSamantha Pozzi, Alessia Bari, Martin Pecherstorfer, et al.
Oncology Letters|June 12, 2025
Real-world evidence of imatinib treatment in younger and older patients with chronic myeloid leukaemia: A retrospective single centre analysisRebecca Graf, Gudrun Kreye, Martin Pecherstorfer, et al.
Molecular and Clinical Oncology|December 6, 2024
Treatment of stage IV colorectal cancer: A retrospective cohort study assessing whether failure of first‑line treatment indicates failure of second‑line treatmentHanna Peyerl, Gudrun Kreye, Martin Pecherstorfer, et al.
Translational Oncology|February 23, 2021
Evaluation of personalized cancer therapies based on comprehensive genomic profiling in a middle-sized oncologic center in Austria, the University Clinic KremsJosef Singer, Elias Brauneck, Elisabeth Zwickl-Traxler, et al.
Oncotarget|July 26, 2018
Tolerability of obinutuzumab therapy in patients with rituximab-relapsed/refractory B-cell malignancies - a retrospective single center cohort studyTheo Pirich, Elisabeth Zwickl-Traxler, Martin Pecherstorfer, et al.
Oncotarget|March 2, 2018
Evaluation of vascular events in patients with myeloproliferative syndromes and mutations of either the januskinase-2 or calreticulin gene at the university hospital Krems from 2008 to 2015Sarah Hintermair, Elisabeth Zwickl-Traxler, Martin Pecherstorfer, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
Evaluation of Ki-67 as a Prognostic Marker in Diffuse Large B-Cell Lymphoma-A Single-Center Retrospective Cohort StudyFabian Huber, Elisabeth Zwickl-Traxler, Martin Pecherstorfer, et al.
Pharmaceutics|October 26, 2018
Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment StrategiesSonia Vallet, Julia-Marie Filzmoser, Martin Pecherstorfer, et al.
Clinical Drug Investigation|December 14, 2006
Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trialMartin Pecherstorfer, Saul Rivkin, Jean-Jacques Body, et al.
Leukemia & Lymphoma|January 19, 2018
A role for bone turnover markers β-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myelomaSonia Vallet, Nicholas R Hoyle, Robert A Kyle, et al.
Pageof 5